drugset / Trial / NCT01294826
Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
The study will determine the maximum tolerated dose (MTD) of AUY922 given in combination with cetuximab in previously treated patients with KRAS wild-type metastatic colorectal cancer.
Timeline
- Start
- 2011-02
- Primary completion
- 2015-05
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AUY922 | Small molecule | 40 mg/m2 | Intravenous |
| Subject | AUY922 | Small molecule | 55 mg/m2 | Intravenous |
| Subject | AUY922 | Small molecule | 70 mg/m2 | Intravenous |
| Background | Cetuximab | Monoclonal antibody | — | Intravenous |